Medications

FDA: Zofran 32-mg dose pulled from market

(HealthDay)—The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according to a Drug Safety ...

Medications

US regulators to decide on new weight loss drug

US regulators were expected to decide Tuesday whether to approve the second new anti-obesity drug in 13 years, Qnexa, which studies have shown may help some people lose up to 10 percent of their body weight.

Medications

New hepatitis C drugs will place strain on health care system

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness ...

page 15 from 40